Pharmafile Logo
Pharmafocus logo
Advanced Search

Martin Shkreli

Showing 15 posts of 20 posts found.

martin_shkreli_house_committee_on_oversight_and_government_reform_2016

Judge rejects Martin Shkreli’s prison release request to work on COVID-19 therapy

May 18, 2020
Sales and Marketing COVID-19, Martin Shkreli, coronavirus

Notorious incarcerated ex-pharma CEO Martin Shkreli has his request rejected to be released from prison in order to research a …

News
martin_shkreli_2016

FDA approves first generic version of Shkreli-hiked toxoplasmosis drug Daraprim

March 2, 2020
Sales and Marketing Cerovene, Daraprim, FDA, Martin Shkreli, generics, pharma

The FDA has awarded approval to the first generic medicine for the treatment of toxoplasmosis, authorising Cerovene’s version of Daraprim …

News

“Pharma Bro” Martin Shkreli charged by FTC for price fixing Daraprim

January 28, 2020
Manufacturing and Production FTC, Martin Shkreli, New York Attorney General, Pharma Bro

Martin Shkreli, also known as the “Pharma Bro”, has been charged by the Federal Trade Commission for price fixing. The …

News
pharmafocus_april_2018_cover

The April 2018 issue of Pharmafocus is now live!

March 27, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Janssen, Martin Shkreli, Right to try, atrial fibrillation, falsified medicines directive, oncology, opioids, pharma

As we finally pass into Spring after what still feels like a particularly stubborn Winter, we are pleased to announce …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

March 16, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Andrew Witty, AstraZeneca, BMS, Biocon, Martin Shkreli, Novartis, Right to try, US, pharma, top ten

Another week goes by, and we may have finally reached Spring here in the UK. Friday means its time for …

News
martin_shkreli_house_committee_on_oversight_and_government_reform_2016

Martin Shkreli sentenced to seven years in jail for securities fraud

March 12, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Martin Shkreli, pharma

Three years after he became “the most hated man in America” overnight for jacking up the price of life-saving HIV-related …

News
martin_shkreli_2016

Martin Shkreli ordered to forfeit $7.36m ahead of fraud sentencing

March 6, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Martin Shkreli, pharma

Reviled pharma bro Martin Shkreli is experiencing another heavy dose of karma after a US judge ordered him to forfeit …

News
martin_shkreli_2016

‘Pharma bro’ Shkreli heads to jail

September 14, 2017
Medical Communications Martin Shkreli, Shkreli, biotech, drugs, pharma, pharmaceutical

Martin Shkreli’s habit of being unable to stay out of the headlines continues, although this time with the repercussion that …

News
martin_shkreli_2016

‘He was born this way’, Shkreli case becomes circus

June 29, 2017
Medical Communications Martin Shkreli, Shkreli, Turing Pharmaceutical, turing

Martin Shkreli’s Attorney, Benjamin Brafman, defended his client in a bizarre reference to a pop singer, “As Lady Gaga would …

News
19199400883_6db786ce0d_b

Price hiking: US pharma’s elephant in the room

October 26, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bernie Sanders, Martin Shkreli, Mylan, Sanofi, Turing Pharmaceuticals, price hikes

Mylan’s recent EpiPen price inflation scandal has reignited a seemingly never-ending debate on the power of drug companies to charge …

Feature
shkreli_kalobios

KaloBios cuts ties with former CEO Martin Shkreli, outlines ‘maniacal’ turnaround plan

August 30, 2016
Research and Development, Sales and Marketing Daraprim, KaloBios, Martin Shkreli, Retrophin, benznidazole, turnaround

Two months after small drugmaker KaloBios returns from bankruptcy, controversial industry figure Martin Shkreli is no longer a stakeholder in …

News
dollars_medicines

KaloBios announces new affordable pricing model, refuses to engage in “price gouging”

April 12, 2016
Manufacturing and Production, Sales and Marketing CEO, Drug pricing, KaloBios, Martin Shkreli, Shkreli, affordable, price gouging, price model, responsible

Price gouging has become synonymous with drug costs in the US, with the infamous Martin Shkreli and troubled Valeant becoming …

News
Shkreli hearing

Big pharma answers tough questions at US drug pricing hearing

February 5, 2016
Medical Communications Drug pricing, FDA, Martin Shkreli, Senate, Turing Pharmaceuticals, US, Valeant, congress

Pharmaceutical industry executives came under intense scrutiny at a Congressional hearing in the US as the debate over the spiralling …

News
martin_shkreli_smaller_same

Martin Shkreli subpoenaed in US to testify over drug pricing

January 21, 2016
Medical Communications, Sales and Marketing Daraprim, Howard Schiller, Martin Shkreli, Valeant, turing

Former pharma chief exec Martin Shkreli has been issued with a subpoena by the US House of representatives, compelling him …

News
NASDAQ

KaloBios files for bankruptcy after Shkreli arrest

January 4, 2016
Sales and Marketing KaloBios, Martin Shkreli

KaloBios has filed for bankruptcy in the wake of chief executive Martin Shkreli’s arrest on securities fraud charges last month …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024